Response evaluation criteria in solid tumors need revision fo use in immunotherapy activity evaluation.
2010
Abstract
Clinical respopnse to immunotherapy may extend beyond those to cytotoxic agents and can manifest after initialk increase in tumor burden- Using the standard (WHO or RECIST) evaluation criteria such response would be classified as progressive disease. That is why new guidlines (immune related response criteria) have been proposed.